Barriers to Access to Hematopoietic Cell Transplantation among Patients with Acute Myeloid Leukemia in Virginia. 2021

Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, Virginia. Electronic address: jdm3fv@virginia.edu.

Allogeneic hematopoietic cell transplantation (HCT) is a standard therapy for patients with intermediate to high-risk acute myeloid leukemia (AML) and is associated with improved long-term disease-free survival. Disparity exists in access to HCT among different patient populations and requires further study. In this study, we compared HCT rates for AML among different regions in the state of Virginia and identified geographic and socioeconomic factors associated with the likelihood of receiving HCT. We conducted a retrospective, cohort study of patients 18 to 74 years of age diagnosed with AML in Virginia from 2013 to 2017 as reported to the Virginia Cancer Registry (VCR); the VCR was further linked with the Center for International Blood and Marrow Transplant Research database for identification of patients who had undergone HCT within 2 years of diagnosis. Socioeconomic data were generated from the VCR and the American Community Survey. Univariate and multivariable logistic regression models were used to examine selected socioeconomic factors of interest, including patient-level information such as sex, age, race, marital status, and primary insurance payer, as well as factors associated with geography, including the Social Vulnerability Index (SVI) and percentage of African Americans residing in the region. In Virginia, 818 patients were diagnosed with AML from 2013 to 2017, and, of these, 168 patients (21%) underwent HCT within 2 years of diagnosis. Median age was lower in the HCT cohort (55 years) versus the non-HCT cohort (64 years) (P < .001). There was a higher proportion of married patients in the HCT cohort (67%) versus the non-HCT cohort (53%) (P = .005). The rate of HCT varied by geographic region (P = .004). The multivariable analyses (without including SVI) showed decreased likelihood of HCT with increasing age (odds ratio [OR], .96; 95% confidence interval [CI], .95 to .98). Patients from regions that had a greater than 25% African American population were less likely to undergo HCT (OR, .58; 95% CI, .38 to .89). Patients who were not married were less likely to undergo HCT compared with married patients (OR, .56; 95% CI, .36 to .88). Patients with government-sponsored insurance as the primary payer were less likely to undergo HCT compared with patients with private insurance (OR, .49; 95% CI, .32 to .77). Patients living in Zip Code areas with a greater percentage of population with a bachelor's or graduate degree were more likely to undergo HCT (OR, 1.02; 95% CI, 1.00 to 1.03). In a separate multivariate model with SVI, patients residing in a Zip Code with higher SVI were less likely to undergo HCT (OR, .37; 95% CI, .16 to .82). From 2013 to 2017, we found that the likelihood of a patient undergoing HCT in Virginia for AML within 2 years of diagnosis was negatively associated with increasing age, percent of African Americans residing in the region, not-married relationship status, government-sponsored insurance as primary payer, higher SVI, and decreased percent of population with a bachelor's or graduate degree. Resources should be directed toward at-risk patient populations to remove barriers to improve access to HCT. The SVI can be used to identify communities at risk nationwide.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014768 Virginia State bounded on the north by Maryland and West Virginia, on the east by the Atlantic Ocean, the Chesapeake Bay and Maryland, and on the south by North Carolina and Tennessee, and on the west by Kentucky and West Virginia.
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
July 2020, Pediatric blood & cancer,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
June 2019, Journal of oncology practice,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
June 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
July 2022, Current oncology (Toronto, Ont.),
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
June 2023, Best practice & research. Clinical haematology,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
December 2023, American journal of hematology,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
June 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
May 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
October 2018, Current treatment options in oncology,
Joseph Mock, and Christa Meyer, and Lih-Wen Mau, and Cecilia Nguyen, and Puja Arora, and Courtney Heron, and Rajesh Balkrishnan, and Linda Burns, and Steven Devine, and Karen Ballen
January 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Copied contents to your clipboard!